Flowvium
Zurück zum Explorer

AbbVie Inc.

ABBVleader

AbbVie is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. While Humira was once the world's best-selling drug, AbbVie has successfully navigated its patent cliff with Skyrizi and Rinvoq, which are on track to exceed Humira's peak revenue combined.

Teilen:
⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($56.3B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Immunology (45%)
Aesthetics/Neuroscience (25%)
Oncology (15%)
Eye Care & Other (15%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Skyrizi / Rinvoq35%

Next-generation immunology biologics replacing Humira revenue

Humira20%

Anti-TNF biologic for rheumatoid arthritis and autoimmune diseases (declining post-LOE)

Botox / Aesthetics25%

Allergan aesthetics portfolio including Botox, Juvederm, and CoolSculpting

Lieferkettenbeziehungen

Wettbewerber

Eli Lilly and Company

Immunology and oncology drugs

Auswirkung: Key therapeutic competitor

Regeneron Pharmaceuticals

Dupixent vs Skyrizi/Rinvoq

Auswirkung: Direct immunology competition

Pfizer Inc.

Broad pharmaceutical portfolio overlap

Auswirkung: Major pharma rival

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Institutionelle Signale

InstitutionAktionWertQuartalEinreichungsdatum
BlackRockaccumulating$717M2024.062024-08-13↑
BlackRockreducing$272M2024.062024-08-13↓
BlackRockreducing$277M2024.062024-08-13↓
BlackRockreducing$21M2024.062024-08-13↓
BlackRockreducing$43M2024.062024-08-13↓
BlackRockaccumulating$507M2024.062024-08-13↑
BlackRockaccumulating$571M2024.062024-08-13↑
BlackRockaccumulating$8.8B2024.062024-08-13↑
BlackRockaccumulating$6.6B2024.062024-08-13↑
BlackRockaccumulating$563M2024.062024-08-13↑
BlackRockaccumulating$923M2024.062024-08-13↑
BlackRockreducing$346M2024.062024-08-13↓
BlackRockaccumulating$608M2024.062024-08-13↑
BlackRockreducing$6M2024.062024-08-13↓
BlackRockaccumulating$1.9B2024.062024-08-13↑
BlackRockreducing$83M2024.062024-08-13↓
BlackRockreducing$30M2024.062024-08-13↓
BlackRockaccumulating$643M2024.062024-08-13↑
BlackRockreducing$64M2024.062024-08-13↓
BlackRockreducing$11M2024.062024-08-13↓
BlackRockreducing$15M2024.062024-08-13↓
BlackRockreducing$399K2024.062024-08-13↓
BlackRockaccumulating$460M2024.062024-08-13↑
Vanguard Groupaccumulating$2.3B2025.122026-01-29↑
Vanguard Groupaccumulating$193M2025.122026-01-29↑
Vanguard Groupaccumulating$37.1B2025.122026-01-29↑
Vanguard Groupaccumulating$754M2025.122026-01-29↑
Vanguard Groupaccumulating$882M2025.122026-01-29↑
Vanguard Groupaccumulating$9M2025.122026-01-29↑
State Streetaccumulating$18.5B2025.122026-02-13↑
Wellington Managementaccumulating$3.1B2025.122026-02-17↑
Wellington Managementaccumulating$65M2025.122026-02-17↑
Wellington Managementreducing$32M2025.122026-02-17↓
Wellington Managementreducing$46M2025.122026-02-17↓
Wellington Managementreducing$24M2025.122026-02-17↓
Wellington Managementreducing$42M2025.122026-02-17↓
Wellington Managementreducing$37M2025.122026-02-17↓
Wellington Managementreducing$5M2025.122026-02-17↓
Wellington Managementaccumulating$93M2025.122026-02-17↑
FMR (Fidelity)accumulating$3.8B2025.122026-02-17↑
FMR (Fidelity)accumulating$280M2025.122026-02-17↑
FMR (Fidelity)accumulating$822M2025.122026-02-17↑
FMR (Fidelity)accumulating$41M2025.122026-02-17↑
FMR (Fidelity)accumulating$218M2025.122026-02-17↑
FMR (Fidelity)accumulating$25M2025.122026-02-17↑

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von AbbVie Inc..

Unternehmensinformationen

Hauptsitz

North Chicago, Illinois, USA

Gegründet

2013

Mitarbeiter

50,000+

Website

abbvie.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Hauptthemen

  • •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
  • •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
  • •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성

Nächste Katalysatoren

  • ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
  • ◆MRNA 암백신 FDA BLA 제출 예정